Tuesday - May 13, 2025
LOUISVILLE, Ky., April 09, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its first quarter 2024 financial results on Thursday, May 2, 2024, prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.
To participate in the conference call, please register here before the 8:30 a.m. ET start. A live and archived webcast of the call will be available on the Company’s investor relations website at https://ir.brightspringhealth.com under the “Events & Presentations” section, where related presentation materials will be posted prior to the conference call. The webcast may be accessed directly here.
BrightSpring will also participate at the upcoming Bank of America 2024 Health Care Conference. Company management will present on Wednesday, May 15, at 9:20 a.m. PT. A live and archived webcast of the presentation will be available on the “Event & Presentations” section of the BrightSpring investor relations website at https://ir.brightspringhealth.com/.
About BrightSpring Health Services
BrightSpring Health Services is the parent company of leading healthcare service lines that provide complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the company’s high-quality and impactful pharmacy, primary care and home health care, and rehabilitation and behavioral health services, and through its skilled and dedicated employees, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily. For more information, visit www.brightspringhealth.com.
Contact
Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
ir@brightspringhealth.com
Media Contact:
Leigh White
leigh.white@brightspringhealth.com
502.630.7412
Last Trade: | US$22.64 |
Daily Change: | 0.29 1.30 |
Daily Volume: | 67,821 |
Market Cap: | US$3.940B |
May 02, 2025 March 06, 2025 November 26, 2024 November 06, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load